Elicera Therapeutics is well-established in the field of cell and gene therapy. Just over a month ago, the company completed patient recruitment for its phase I/II study with ELC-100. Results from the first part of the study are expected in H1 2025. BioStock spoke with CEO Jamal el-Mosleh to hear his thoughts on this achievement.
Read the interview at biostock.se:
https://www.biostock.se/en/2024/11/eliceras-ceo-elc-100-stands-apart-from-all-other-standard-treatments/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/
